HC Wainwright Predicts Increased Earnings for Pyxis Oncology

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Pyxis Oncology to ($0.37) EPS, improving from the previous estimate of ($0.40), while maintaining a "Buy" rating with a price target of $5.00.
• Pyxis Oncology recently reported earnings of ($0.30) per share for the last quarter, exceeding the consensus estimate of ($0.36) by $0.06, with revenues totaling $2.82 million.
• Zacks Research has upgraded Pyxis Oncology's rating from "strong sell" to "hold", while it currently has a consensus rating of "Moderate Buy" and a price target of $8.67.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for Pyxis Oncology in a research report issued to clients and investors on Tuesday, August 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.37) per share for the quarter, up from their prior forecast of ($0.40). HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at $0.33 EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.20 EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.82 million during the quarter.

Separately, Zacks Research upgraded shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research report on Monday. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.67.

Pyxis Oncology Trading Down 3.3%

NASDAQ:PYXS opened at $1.16 on Thursday. The company has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.15. The stock has a market cap of $71.94 million, a price-to-earnings ratio of -0.72 and a beta of 1.13. Pyxis Oncology has a 12 month low of $0.8332 and a 12 month high of $5.3899.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in shares of Pyxis Oncology by 83.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock valued at $458,000 after purchasing an additional 133,018 shares during the last quarter. Barclays PLC increased its position in Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company's stock valued at $121,000 after buying an additional 12,924 shares in the last quarter. Marshall Wace LLP raised its stake in Pyxis Oncology by 35.7% during the fourth quarter. Marshall Wace LLP now owns 157,953 shares of the company's stock valued at $246,000 after buying an additional 41,594 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Pyxis Oncology by 35.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 111,051 shares of the company's stock valued at $173,000 after buying an additional 29,105 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in Pyxis Oncology by 36.6% in the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock worth $106,000 after acquiring an additional 18,128 shares in the last quarter. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.